Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) Income from Continuing Operations: 2014-2025

Historic Income from Continuing Operations for KalVista Pharmaceuticals (KALV) over the last 7 years, with Apr 2025 value amounting to -$42.3 million.

  • KalVista Pharmaceuticals' Income from Continuing Operations rose 5.34% to -$42.3 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$156.4 million, marking a year-over-year decrease of 65.27%. This contributed to the annual value of -$183.5 million for FY2025, which is 44.86% down from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported Income from Continuing Operations of -$42.3 million as of Q2 2025, which was down 4.51% from -$40.4 million recorded in Q3 2024.
  • KalVista Pharmaceuticals' Income from Continuing Operations' 5-year high stood at -$29.0 million during Q1 2024, with a 5-year trough of -$44.6 million in Q2 2024.
  • For the 2-year period, KalVista Pharmaceuticals' Income from Continuing Operations averaged around -$39.1 million, with its median value being -$41.4 million (2024).
  • Data for KalVista Pharmaceuticals' Income from Continuing Operations shows a peak YoY grew of 5.34% (in 2025) over the last 5 years.
  • KalVista Pharmaceuticals' Income from Continuing Operations (Quarterly) stood at -$40.4 million in 2024, then climbed by 5.34% to -$42.3 million in 2025.
  • Its Income from Continuing Operations was -$42.3 million in Q2 2025, compared to -$40.4 million in Q3 2024 and -$44.6 million in Q2 2024.